Spironolactone to Improve Apnea and Cardiovascular Markers in Obstructive Sleep Apnea Patients

Withdrawn before enrolling · Phase 4 · Has a placebo group

Conditions studied: Obstructive Sleep Apnea

In brief

The purpose of this study is to test whether Spironolactone can improve the severity of obstructive sleep apnea and improve cardiovascular biomarkers in people who are not regularly using their Positive Airway Pressure (PAP) therapy.

Key facts

Study ID
NCT04205136
Run by
University of Michigan
People needed
0
Starts
2022-03-01
Expected to finish
2023-04-01
Last updated by the study team
2022-04-19

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.